BeOne Medicines (NASDAQ:ONC) SVP Chan Henry Lee Sells 664 Shares of Stock

BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) SVP Chan Henry Lee sold 664 shares of the firm’s stock in a transaction dated Wednesday, July 8th. The shares were sold at an average price of $302.46, for a total transaction of $200,833.44. Following the sale, the senior vice president owned 202 shares of the company’s stock, valued at approximately $61,096.92. This represents a 76.67% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Chan Henry Lee also recently made the following trade(s):

• On Tuesday, June 16th, Chan Henry Lee sold 590 shares of BeOne Medicines stock. The stock was sold at an average price of $265.98, for a total transaction of $156,928.20.
• On Thursday, June 11th, Chan Henry Lee sold 428 shares of BeOne Medicines stock. The shares were sold at an average price of $257.63, for a total transaction of $110,265.64.
• On Monday, June 8th, Chan Henry Lee sold 871 shares of BeOne Medicines stock. The shares were sold at an average price of $270.42, for a total transaction of $235,535.82.
• On Wednesday, May 13th, Chan Henry Lee sold 332 shares of BeOne Medicines stock. The shares were sold at an average price of $310.72, for a total transaction of $103,159.04.

BeOne Medicines Stock Down 1.4%

NASDAQ ONC traded down $4.13 during mid-day trading on Friday, reaching $298.70. The stock had a trading volume of 232,186 shares, compared to its average volume of 263,256. BeOne Medicines Ltd. – Sponsored ADR has a 1 year low of $249.00 and a 1 year high of $385.22. The stock has a market cap of $32.77 billion, a PE ratio of 66.82 and a beta of 0.49. The company has a fifty day moving average price of $289.73 and a 200 day moving average price of $309.10. The company has a debt-to-equity ratio of 0.20, a current ratio of 3.64 and a quick ratio of 3.27.

BeOne Medicines (NASDAQ:ONC) last issued its earnings results on Wednesday, April 1st. The company reported $0.25 EPS for the quarter. The business had revenue of $1.51 billion for the quarter. BeOne Medicines had a return on equity of 12.06% and a net margin of 8.94%. On average, research analysts expect that BeOne Medicines Ltd. – Sponsored ADR will post 5.86 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. EFG International AG purchased a new stake in shares of BeOne Medicines in the 4th quarter worth $25,000. Leonteq Securities AG bought a new position in BeOne Medicines in the 4th quarter worth $35,000. Daiwa Securities Group Inc. purchased a new position in BeOne Medicines during the second quarter valued at $35,000. CWM LLC lifted its position in BeOne Medicines by 32.8% during the fourth quarter. CWM LLC now owns 158 shares of the company’s stock valued at $48,000 after purchasing an additional 39 shares in the last quarter. Finally, Group One Trading LLC bought a new stake in BeOne Medicines during the fourth quarter valued at about $61,000. 48.55% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on ONC shares. Wells Fargo & Company assumed coverage on BeOne Medicines in a research report on Monday, May 4th. They set an “overweight” rating and a $400.00 price objective on the stock. Wolfe Research began coverage on BeOne Medicines in a research report on Friday, March 27th. They issued an “outperform” rating and a $340.00 target price for the company. Barclays upped their target price on shares of BeOne Medicines from $405.00 to $409.00 and gave the company an “overweight” rating in a research note on Thursday, May 7th. Truist Financial raised their price target on shares of BeOne Medicines from $413.00 to $416.00 and gave the company a “buy” rating in a report on Tuesday. Finally, Wall Street Zen lowered shares of BeOne Medicines from a “strong-buy” rating to a “buy” rating in a research note on Monday. One analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, BeOne Medicines has an average rating of “Moderate Buy” and a consensus target price of $391.38.

BeOne Medicines Company Profile

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.